Molecular Assessment of Artemisinin Resistance Markers in Eastern and Western Border Areas of Myanmar

Molecular Assessment of Artemisinin Resistance Markers, K13 Kelch Propeller and Multi-drug Resistant Gene Polymorphism in Eastern and Western Border Areas of Myanmar

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02198573

Enrollment

Registered

2014-07-23

Start date

2013-07-31

Completion date

2014-06-30

Last updated

2014-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Day-3 Positive of Parasitaemia, Prevalence of Drug Resistance Gene Mutation

Keywords

malaria, K13, pfmrp1, Myanmar

Brief summary

* Artemisinin resistance have been documented in Myanmar and Myanmar artemisinin resistance containment measures have been launched since 2009-2010. * It is important to monitor the spread and magnitude of artemisinin resistant malaria in Myanmar. * So, day-3 surveillance study have been conducted. * Recently artemisinin resistant molecular marker, K13 have been identified and it was used as a tool in this study.

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

2 Years to No maximum

Healthy volunteers

Inclusion criteria

* confirmed uncomplicated falciparum malaria patients. * age \>2 years * box sex * given informed consent

Exclusion criteria

* severe malaria * did not give informed consent * others diseases

Design outcomes

Primary

Measure	Time frame	Description
day-3 parasite positivity	3 days	All of the enrolled patients were monitored with appropriate care up to third day and take the samples on day-3.

Secondary

Measure	Time frame	Description
Prevalence of the drug resistance marker	up to day-3	By using the dried blood spots, drug resistance markers were detected by molecular method.

Countries

Burma

Outcome results